{"title": "Respuesta vacunal frente a SARS-CoV-2 en trabajadores de un hospital", "author": "Susana Sabater Vidal; M\u00aa Carmen Bellido-Cambr\u00f3n; Alberto Arnedo-Pena; M\u00aa Isabel Palomares-Gallego; Rosa Mar\u00eda Larrea-Gonz\u00e1lez; Mario Carballido-Fern\u00e1ndez; Rosario Moreno-Mu\u00f1oz", "url": null, "hostname": null, "description": "Introduction: The aim of this study was to measure anti-SARS-CoV-2 immunity of hospital workers after a completed 2-dose Pfizer-BionTech vaccination, and to examine factors potentially associated with immunity status. Side effects of the vaccine were also studied. Method: This was a cross-sectional study of a representative sample of General University Hospital of Castellon workers, vaccinated with two doses in January and February 2021. We measured IgG antibodies against protein N (IgG-NP), IgM against protein S (IgM-S), and quantitative levles of IgG against protein S (IgG-Quant) one month after the last dose. We obtained information on demographic, risk factors, and vaccine side effects via a self-completed questionnaire. For the statistical analysis we used multiple regression models. Results: Two hundred seventy-five workers participated (96.8%, 275/284). Positive IgG-Quant, IgM-S, and IgG-NP were 99.6%, 14.9% and 4.4%, respectively. Adjusted IgG-Quant levels increased significantly with obesity, nonsmoking status, positive IgM-S, and/or IgG-NP. The prevalence of IgM-S was higher in males, and associated with the same factors as those for IgG-Quant. Among those with a history of COVD-19 infection, 42.9% did not have IgG-NP. Overall 86.5% of participants had side effects, which were associated with positive IgG-NP, high IgG-Quant levels, younger age, and being female. Conclusions: All but one participant developed immunity. Those who had suffered from COVID-19 infection had higher antibody levels. A high proportion of participants had mild secondary effects, especially those with previous COVID-19 infection.", "sitename": "Archivos de Prevenci\u00f3n de Riesgos Laborales", "date": "2021-10-15", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Resumen\nIntroducci\u00f3n: Evaluar la inmunidad de los trabajadores de un hospital tras haber completado la vacunaci\u00f3n Pfizer-BionTech, y su relaci\u00f3n con factores individuales. Tambi\u00e9n describir los efectos adversos de la vacuna.\nM\u00e9todo: Estudio transversal de una muestra de los trabajadores del Hospital General Universitario de Castell\u00f3n vacunados con dos dosis en enero y febrero de 2021. Un mes despu\u00e9s se detectaron: anticuerpos IgG frente a la prote\u00edna N (IgG-NP), de IgM frente a la prote\u00edna S (IgM-S) y detecci\u00f3n cuantitativa de IgG frente a la prote\u00edna S (IgG-Quant). Se utiliz\u00f3 un cuestionario para recoger datos demogr\u00e1ficos, factores de riesgo y efectos secundarios. En el an\u00e1lisis estad\u00edstico se utilizaron modelos de regresi\u00f3n m\u00faltiple.\nResultados: La participaci\u00f3n fue del 96,8% (275/284). Presentaron IgG-Quant el 99,6%, 14,9% IgM-S, y 4,4% IgG-NP. El nivel ajustado de IgG-Quant aument\u00f3 significativamente con la obesidad, en no fumadores y con positividad IgM-S y/o IgG-NP. La prevalencia de IgM-S era mayor en varones, y se asociaba con los mismos factores que la IgG-Quant. De los infectados por COVID-19, el 42,9% no presentaron IgG-NP. Un 86,5% sufri\u00f3 alg\u00fan efecto secundario que se asoci\u00f3 a tener IgG-NP, mayores niveles de IgG-Quant, y fue m\u00e1s frecuente en j\u00f3venes y mujeres.\nConclusiones: Todos los participantes desarrollaron inmunidad humoral excepto uno. Tuvieron mayores niveles de anticuerpos los que hab\u00edan padecido la COVID-19. Un porcentaje alto desarroll\u00f3 efectos secundarios leves, m\u00e1s frecuentes en los que hab\u00edan padecido la enfermedad.\nCitas\nReina J. El SARS-CoV-2, una nueva zoonosis pand\u00e9mica que amenaza al mundo. Vacunas. 2020;21(1):17\u201322. doi:10.1016/j.vacun.2020.03.001.\nUllah H, Ullah A, Gull A, Mousavi T, Khan MW. Novel Coronavirus 2019 (COVID-19) Pandemic Outbreak: A Comprehensive Review of the Current Literature. Vacunas. 2021;22(2):106-113.\nM\u00e9dicos Sin Fronteras. Informe sobre la protecci\u00f3n del personal sanitario durante la COVID-19 en Espa\u00f1a. Barcelona: M\u00e9dicos Sin Fronteras; 2020 [citado 25 Ago 2021]. Disponible en:\n[https://www.msf.es/sites/default/files/documents/msf-informe-covid19-proteccion-web01.pdf](https://www.msf.es/sites/default/files/documents/msf-informe-covid19-proteccion-web01.pdf)\nInstituto de Salud Carlos III, Centro Nacional de Epidemiolog\u00eda, Red Nacional de Vigilancia Epidemiol\u00f3gica. An\u00e1lisis de los casos de COVID-19 en personal sanitario notificados a la Red Nacional de Vigilancia Epidemiol\u00f3gica (RENAVE) hasta el 10 de mayo en Espa\u00f1a. 2020 [citado 25 Ago 2021]. Disponible en:\n[https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/COVID-19%20en%20personal%20sanitario%2029%20de%20mayo%20de%202020.pdf](https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/COVID-19%20en%20personal%20sanitario%2029%20de%20mayo%20de%202020.pdf)\nAmit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877.\nBelete TM. A review on Promising vaccine development progress for COVID-19 disease. Vacunas. 2020;21(2):121-128.\nCamara C, Lozano-Ojalvo D, Lopez-Granados E, Paz-Artal E, Pion M, Rafael Correa-Rocha R, et al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in na\u00efve and COVID-19 recovered individuals. Cell Rep. 2021;36(8):109570.\nSharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:585354.\nPolack FP, Thomas SJ, Kitchin N, AbsalonJ, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615.\nNarasimhan M, Mahimainathan L, Araj E, Clark AE, Markantonis J, Green A, Xu J et al. Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups. J Clin Microbiol. 2021;59(7):e0038821.\nEpi Info version 7. Atlanta: Centers for Disease Control and Prevention 2013. [citado 25 Ago 2021]. Disponible en:\n[https://www.cdc.gov/epiinfo](https://www.cdc.gov/epiinfo)\nPolack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.\nOliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The Advisory Committee on Immunization Practices\u2019 Interim recommendation for use of Pfizer-BioNTech COVID-19 Vaccine. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922-1924.\nVarona JF, Madurga R, Pe\u00f1alver F, Abarca E, Almirall C, Cruz, et al. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain. Int J Epidemiol. 2021;50(2):400-409.\nBarallat J,Fern\u00e1ndez-Rivas G, Quirant-S\u00e1nchez B, Gonz\u00e1lez V, Dolad\u00e9 M, Martinez-Caceres E, et al. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. PLoS One. 2020;15(12):e0244348.\nDean AG, Sullivan KM, Soe MM. Open Source Epidemiologic Statistics for Public Health (OpenEpi), Version 2013. [citado 25 Ago 2021]. Disponible en:\n[https://www.openepi.com/Menu/OE_Menu.htm](https://www.openepi.com/Menu/OE_Menu.htm)\nTextor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019. Int J Epidemiol. 2016;45:1887-1894.\nM\u00fcller L, Andr\u00e9e M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021:ciab381.\nAbu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26:2100096.\nSoiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50(2):279-283.\nBoss\u00e9 Y, Xiao F, Kheradmand F, Amos CI. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;201(12):1557-1559.\nBrake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020;9(3):841.\nWatanabe M, Balena A, Tuccinardi D, TozziR, Risi R, Masi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2021:e3465.\nGrzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et al. Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2. J Infect Dis. 2021:jiab127.\nGerhards C, Thiaucourt M, Kittel M, Becker C, Ast V, Hetjens M, et al. Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J Infect Dis. 2021;107:221-227.\nPellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, et al. Initial observations on age, gender, BMI and hypertension in antibody response to SARS-CoV-2 BNT162b2 vaccine. E Clinical Medicine 2021:100928.\nSoffer S, Glicksberg BS, Zimlichman E, Efros O, Levin MA, Freeman R, et al. The association between obesity and peak antibody titer response in COVID-19 infection. Obesity (Silver Spring). 2021:10.1002/oby.23208.\nManisty C, Otter AD, Treibel TA, McKnight \u00c1, Altmann DM, Brooks T, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397:1057-1058.\nTr\u00e9-Hardy M, Cupaiolo R, Papleux E, Wilmet A, Horeanga A, Antoine-Moussiaux T, et al. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. J Infect. 2021:S0163-4453(21)00158-4.\nKrammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372-1374.\nFavresse J, Bayart JL, Mullier F, Dogn\u00e9 JM, Closset M, Douxfils J. Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021:S1198-743X(21)00224-X.\nSchaffner A, Risch L, Aeschbacher S, Risch C, Weber MC, Thiel SL, et al. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. J Clin Med. 2020;9(12):3989.\nHarris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. J Infect. 2021;82(5):162-169.\nCallegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, et al. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection. J Med Virol. 2021;93(7):4612-4615.\nRuiz-Galiana J, Cant\u00f3n R, De Lucas-Ramos P, Garc\u00eda-Botella A, Garc\u00eda-Lled\u00f3 A, G\u00f3mez-Pav\u00f3n J, et al. Vacunaci\u00f3n anti-COVID-19: La realidad tras los ensayos cl\u00ednicos. Rev Esp Quimioter. 2021:ruiz28apr2021.\nLos autores que publican en esta revista est\u00e1n de acuerdo con los siguientes t\u00e9rminos:\nLos autores/as conservar\u00e1n sus derechos de autor y garantizar\u00e1n a la revista el derecho de primera publicaci\u00f3n de su obra, el cu\u00e1l estar\u00e1 simult\u00e1neamente sujeto a la Licencia de reconocimiento de\n[Creative Commons 4.0 BY-NC-ND](http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES).\nLos autores/as podr\u00e1n adoptar otros acuerdos de licencia no exclusiva de distribuci\u00f3n de la versi\u00f3n de la obra publicada (p. ej.: depositarla en un archivo telem\u00e1tico institucional o publicarla en un volumen monogr\u00e1fico) siempre que se indique la publicaci\u00f3n inicial en esta revista.\nSe permite y recomienda a los autores/as difundir su obra a trav\u00e9s de Internet (p. ej.: en archivos telem\u00e1ticos institucionales o en su p\u00e1gina web) antes y durante el proceso de env\u00edo, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (V\u00e9ase\n[El efecto del acceso abierto](http://opcit.eprints.org/oacitation-biblio.html)).", "language": null, "image": null, "pagetype": null, "links": ["\thttps://archivosdeprevencion.eu/index.php/aprl/index\n", "\thttps://archivosdeprevencion.eu/index.php/aprl/index\n", "https://archivosdeprevencion.eu/index.php/aprl/about", "https://archivosdeprevencion.eu/index.php/aprl/about", "https://archivosdeprevencion.eu/index.php/aprl/about/submissions", "https://archivosdeprevencion.eu/index.php/aprl/ethics", "http://archivosdeprevencion.eu/index.php/aprl/peerreview", "https://archivosdeprevencion.eu/index.php/aprl/indexed", "https://archivosdeprevencion.eu/index.php/aprl/about/privacy", "https://archivosdeprevencion.eu/index.php/aprl/about/contact", "https://archivosdeprevencion.eu/index.php/aprl/antiplagio", "https://archivosdeprevencion.eu/index.php/aprl/interoperabilidad", "http://archivosdeprevencion.eu/index.php/aprl/avisolegal", "http://archivosdeprevencion.eu/index.php/aprl/cookies", "https://archivosdeprevencion.eu/index.php/aprl/about/editorialTeam", "https://archivosdeprevencion.eu/index.php/aprl/issue/current", "http://archivosdeprevencion.eu/index.php/aprl/issue/archive", "http://archivosdeprevencion.eu/index.php/aprl/numeros2019", "https://archivosdeprevencion.eu/index.php/aprl/issue/archive", "http://archivosdeprevencion.eu/index.php/aprl/referees", "https://archivosdeprevencion.eu/index.php/aprl/supp", "https://archivosdeprevencion.eu/index.php/aprl/colecciones", "https://archivosdeprevencion.eu/index.php/aprl/ednotes", "https://archivosdeprevencion.eu/index.php/aprl/referees", "https://archivosdeprevencion.eu/index.php/aprl/announcement", "https://archivosdeprevencion.eu/index.php/aprl/search/search", "https://archivosdeprevencion.eu/index.php/aprl/user/register", "https://archivosdeprevencion.eu/index.php/aprl/login", "https://archivosdeprevencion.eu/index.php/aprl/user/setLocale/en_US?source=%2Findex.php%2Faprl%2Farticle%2Fview%2F159", "https://archivosdeprevencion.eu/index.php/aprl/user/register", "https://archivosdeprevencion.eu/index.php/aprl/login", "https://archivosdeprevencion.eu/index.php/aprl/user/setLocale/en_US?source=%2Findex.php%2Faprl%2Farticle%2Fview%2F159", "https://archivosdeprevencion.eu/index.php/aprl/issue/view/9", "https://archivosdeprevencion.eu/index.php/aprl/issue/view/9", "https://doi.org/10.12961/aprl.2021.24.04.05", "#author-1", "https://orcid.org/0000-0003-3591-5721", "#author-2", "#author-3", "#author-4", "#author-5", "#author-6", "#author-7", "https://orcid.org/0000-0003-3591-5721", "https://archivosdeprevencion.eu/index.php/aprl/issue/view/9", "https://archivosdeprevencion.eu/index.php/aprl/article/view/159/110", "https://archivosdeprevencion.eu/index.php/aprl/catalog/category/covid19", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/acm-sig-proceedings?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/acs-nano?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/apa?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/associacao-brasileira-de-normas-tecnicas?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/chicago-author-date?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/harvard-cite-them-right?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/ieee?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/modern-language-association?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/turabian-fullnote-bibliography?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/get/vancouver?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/download/ris?submissionId=159&publicationId=132", "https://archivosdeprevencion.eu/index.php/aprl/citationstylelanguage/download/bibtex?submissionId=159&publicationId=132", "https://doi.org/10.12961/aprl.2021.24.04.05", "https://archivosdeprevencion.eu/index.php/aprl/article/view/159/110", "https://www.msf.es/sites/default/files/documents/msf-informe-covid19-proteccion-web01.pdf", "https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/COVID-19%20en%20personal%20sanitario%2029%20de%20mayo%20de%202020.pdf", "https://www.cdc.gov/epiinfo", "https://www.openepi.com/Menu/OE_Menu.htm", "http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES", "http://opcit.eprints.org/oacitation-biblio.html", "https://archivosdeprevencion.eu/index.php/aprl/information/readers", "https://archivosdeprevencion.eu/index.php/aprl/information/authors", "https://archivosdeprevencion.eu/index.php/aprl/information/librarians", "https://archivosdeprevencion.eu/index.php/aprl/about/submissions", "http://www.academia.cat/", "http://www.academia.cat/Portal/Avis-Legal/_3s2AGOzVQfrfji4iQnZmFQ3SfNlo0Rdx", "https://archivosdeprevencion.eu/index.php/aprl/about/aboutThisPublishingSystem", "https://archivosdeprevencion.eu/index.php/aprl/login/lostPassword", "https://archivosdeprevencion.eu/index.php/aprl/user/register?source="]}